Pancreatic Cancer Research

ResearcherFlorida Agricultural and Mechanical UniversityActive in the last 2 years

Edward Agyare

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6905-5136; OpenAlex author ID A5004372213; NIH RePORTER profile ID 11735026. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 11)
Trials
0
Grants
1
Labs led
1
Collaborators
32
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers, 1 grant

Papers 16

  1. Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expressed pancreatic cancer. Last author DOI 10.1016/j.ijpx.2026.100544↗
  2. Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models. Last author DOI 10.1177/15330338261468414↗
  3. Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. Co-author DOI 10.1371/journal.pone.0326550↗
  4. ECM Stiffness-Induced Redox Signaling Enhances Stearoyl Gemcitabine Efficacy in Pancreatic Cancer. First author DOI 10.3390/cancers17050870↗
  5. Cachexia in Pancreatic Cancer: New Insights to Impact Quality of Life and Survival. Co-author DOI 10.3390/nu17193064↗
  6. Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic canc… Last author DOI 10.1016/j.ejps.2024.106754↗
  7. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. Co-author DOI 10.1016/j.jnma.2023.01.008↗
  8. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. Last author DOI 10.1186/s12885-023-10928-w↗
  9. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. Last author DOI 10.3390/ijms24054288↗
  10. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. Last author DOI 10.1186/s12885-022-10449-y↗
  11. Application of modified gemcitabine-loaded solid lipid nanoparticle in the treatment of pancreatic cancer patient-derived xenograft model Last author DOI 10.21203/rs.3.rs-1777458/v1↗
  12. Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells. Last author DOI 10.1016/j.jddst.2019.101374↗
  13. Comparative study on contrast enhancement of Magnevist and Magnevist-loaded nanoparticles in pancreatic cancer PDX model monitored by MRI. Last author DOI 10.1186/s12645-020-00061-9↗
  14. Pancreatic Cancer Related Health Disparities: A Commentary. Co-author DOI 10.3390/cancers10070235↗
  15. Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines. Last author PMID 26090123↗
  16. In vitro and in vivo antitumor activity of gemcitabine loaded thermosensitive liposomal nanoparticles and mild hyperthermia in pancreatic cancer. Last author PMID 26677454↗

Grants 1

  1. Community Outreach Core U54CA233396↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bo Han · 10 shared papers, 2020–2025 · strength 2.01
  2. Esther Frimpong · 8 shared papers, 2022–2026 · strength 1.70
  3. Raviteja Bulusu · 7 shared papers, 2022–2026 · strength 1.51
  4. Sherise Chantell Rogers · 5 shared papers, 2023–2025 · strength 1.10
  5. Joy C. Okoro · 4 shared papers, 2023–2026 · strength 1.03
  6. Andriana Inkoom · 5 shared papers, 2022–2024 · strength 0.88
  7. Nkafu Bechem Ndemazie · 5 shared papers, 2022–2024 · strength 0.88
  8. Jose Gilberto Trevino · 6 shared papers, 2018–2023 · strength 0.81
  9. Thomas D. Schmittgen · 1 shared paper, 1 shared grant, 2018–2026 · strength 0.70
  10. Saunjoo L. Yoon · 3 shared papers, 2018–2025 · strength 0.66
  11. Hernan Alcides Flores-Rozas · 1 shared grant, 2026 · strength 0.63
  12. Gebre-Egziabher Kiros · 1 shared grant, 2026 · strength 0.63
  13. Jamel Ali · 1 shared grant, 2026 · strength 0.63
  14. Saunjoo Yoon · 2 shared papers, 2026 · strength 0.63
  15. Eun Lee · 1 shared grant, 2026 · strength 0.63
  16. Sandra G Suther · 1 shared grant, 2026 · strength 0.63
  17. Romonia Renee REAMS · 1 shared grant, 2026 · strength 0.63
  18. Jonathan Barajas · 2 shared papers, 2025 · strength 0.54
  19. Sunil Krishnan · 2 shared papers, 2020–2026 · strength 0.44
  20. Kevin Affram · 4 shared papers, 2015–2020 · strength 0.41
  21. Diana J. Wilkie · 2 shared papers, 2018–2025 · strength 0.36
  22. Shuqing Zhao · 1 shared paper, 2025 · strength 0.24
  23. Ba X. Hoang · 1 shared paper, 2025 · strength 0.24
  24. Enrique I. Velazquez-Villarreal · 1 shared paper, 2025 · strength 0.24
  25. John M. Allen · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.